Contrasting of Curis Inc. (CRIS) and Ascendis Pharma A/S (NASDAQ:ASND)

Both Curis Inc. (NASDAQ:CRIS) and Ascendis Pharma A/S (NASDAQ:ASND) are Biotechnology companies, competing one another. We will contrast their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Curis Inc. 10.94M 3.30 34.66M -1.05 0.00
Ascendis Pharma A/S N/A 0.00 N/A -3.81 0.00

In table 1 we can see Curis Inc. and Ascendis Pharma A/S’s gross revenue, earnings per share and valuation.


Table 2 shows the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Curis Inc. -316.82% -299.1% -59.6%
Ascendis Pharma A/S 0.00% -45.2% -41.3%

Risk and Volatility

Curis Inc. has a beta of 1.23 and its 23.00% more volatile than Standard & Poor’s 500. In other hand, Ascendis Pharma A/S has beta of 0.85 which is 15.00% less volatile than Standard & Poor’s 500.


2.6 and 2.6 are the respective Current Ratio and a Quick Ratio of Curis Inc. Its rival Ascendis Pharma A/S’s Current and Quick Ratios are 10.5 and 10.5 respectively. Ascendis Pharma A/S has a better chance of clearing its pay short and long-term debts than Curis Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Curis Inc. and Ascendis Pharma A/S.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Curis Inc. 0 0 0 0.00
Ascendis Pharma A/S 0 0 3 3.00

Competitively the consensus price target of Ascendis Pharma A/S is $91, which is potential 29.30% upside.

Insider and Institutional Ownership

Institutional investors held 30.6% of Curis Inc. shares and 96% of Ascendis Pharma A/S shares. Curis Inc.’s share held by insiders are 18.27%.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Curis Inc. -19.68% -56.68% -53.46% -70.81% -83.59% -80.32%
Ascendis Pharma A/S -6.68% -3.18% -2.1% -9.17% 69.77% 57.26%

For the past year Curis Inc. has -80.32% weaker performance while Ascendis Pharma A/S has 57.26% stronger performance.


Ascendis Pharma A/S beats Curis Inc. on 7 of the 10 factors.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.